Health Editor’s Note: Information needed to fully evaluate opioid distribution in the U.S., for an upcoming trial against pharmaceutical companies, is not going to be released. Untraceable money is the fuel for pharma lobbying against the Affordable Care Act. It is not enough that big pharma robs us when we get those prescriptions filled, they tirelessly work behind the scenes to undermine anything that will cut into their ill-gained profits at great cost to Americans and the delivery of American health care…Carol
Health Care Investigations
Greg Portz of Medpage Today
Opioid Data to Remain Secret
Judge Keeps Opioid Info Under Wraps
A federal judge ruled against the release of opioid distribution data, to the disappointment of journalists investigating the crisis. The move comes ahead of an anticipated 2019 trial against pharmaceutical companies that develop, distribute, and sell the drugs. Keeping secret the information on where and in what quantities the drugs are dispersed across the country was part of the terms these drugmakers made when initially turning over the data to the U.S. Drug Enforcement Agency.
Pharma’s Dark Money Targeted ACA
Kaiser Health News details a web of dark-money pharma lobbying and how it is affecting healthcare in the U.S. “Dark money” is money funneled through non-profits and trade associations, among others, that cannot easily be traced. On the pharmaceutical side, the largest such trade group in the country is Pharmaceutical Research and Manufacturers of America (PhRMA), whose contributions to the conservative American Action Network (AAN), a lobbying group that spent millions to try to get the Affordable Care Act repealed, is raising eyebrows.
Did the recipients of PhRMA’s multi-million dollar donations, like AAN, push PhRMA’s agenda without revealing its role?